Last updated: February 8, 2026
What is the Current Status of CORTROPHIN-ZINC in Clinical Trials?
CORTROPHIN-ZINC is primarily used as a nutritional supplement and alternative therapy for respiratory infections. It combines human placental hydrolysates, corticotropin (ACTH), and zinc.
As of now, there are no publicly available, officially registered clinical trials registered on ClinicalTrials.gov or other major registries specifically evaluating CORTROPHIN-ZINC for any medical condition. The drug has been used in certain regions, notably in India, for decades without the completion of large-scale, randomized controlled trials (RCTs). Its use predominantly relies on traditional usage, limited clinical data, and observational studies.
Summary of Trial Landscape
| Status |
Details |
| Number of registered trials |
Zero formally registered at major clinical trial registries |
| Type of studies |
Mostly observational, anecdotal reports, case series |
| Regulatory approval |
Approved in some countries (e.g., India) for specific indications, but lacks global approval |
| Ongoing Phase 3 trials |
None reported |
What Does Market Analysis Reveal About CORTROPHIN-ZINC?
Geographical Markets
The dominant market for CORTROPHIN-ZINC is India, where it has been part of the authorized therapeutic options for respiratory infections and zinc deficiency-related conditions. It is available as an over-the-counter supplement and prescription product. Outside India, the drug has minimal availability and recognition, mainly due to limited clinical evidence and regulatory approval.
Regulatory Environment
In India, the Central Drugs Standard Control Organization (CDSCO) has not officially classified CORTROPHIN-ZINC as a drug for any specific indication but permits its sale as a nutritional supplement or herbal remedy. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This limits its entry into the Western markets and hampers global commercialization efforts.
Market Size and Growth Drivers
The Indian market for traditional and herbal medicines is estimated at USD 4.4 billion in 2022, growing annually at around 9% (FICCI and Pharmexcil reports). CORTROPHIN-ZINC's role as a respiratory aid positions it within this ecosystem, particularly during flu seasons and the COVID-19 pandemic, where demand for immune-boosting products surged.
However, the lack of rigorous clinical validation constrains its potential growth outside the domestic market.
Competitive Landscape
CORTROPHIN-ZINC faces competition from:
- Zinc supplements from global pharmaceutical companies
- Traditional herbal formulations with claimed immunomodulatory effects
- Pharmaceutical drugs approved for respiratory infections and zinc deficiency treatment (e.g., zinc gluconate, zinc acetate)
Given the absence of high-quality data, its market position relies heavily on traditional usage, physician preference in India, and patient demand for natural and immune-boosting supplements.
What Are Future Market Projections?
Short-term Outlook (Next 2 Years)
- Market Penetration: Limited outside India. Small growth expected in regions with high acceptance of herbal and alternative medicines, such as Southeast Asia and Middle East.
- Regulatory Hurdles: No significant regulatory endorsements expected without new clinical data.
- Potential Drivers: Increased interest during viral outbreaks, ethnic and herbal medicine trends.
Long-term Outlook (3-10 Years)
- Research Development: Potential for renewed interest if new clinical trials can demonstrate efficacy and safety.
- Market Expansion: Contingent upon global regulatory approval and positive clinical evidence.
- Investment Potential: Uncertain, given the current paucity of rigorous data, but high if formal RCTs establish clear efficacy.
Market Forecast Estimates
| Year |
Estimated Global Market for similar immunomodulatory supplements (USD) |
CORTROPHIN-ZINC Specific |
Comments |
| 2023 |
6 billion |
Small niche |
Mainly Indian traditional medicine segment |
| 2025 |
8 billion |
Moderate growth |
Growing interest in immune health post-pandemic |
| 2030 |
12 billion |
Uncertain |
Dependent on regulatory approvals and clinical proof |
What Are the Key Challenges and Opportunities?
Challenges
- Absence of large-scale, peer-reviewed RCTs proving efficacy and safety
- Limited regulatory recognition outside India
- Variations in preparation, dosage, and formulation impact standardization
- Competition from well-established, evidence-backed zinc and herbal supplements
Opportunities
- Conducting rigorous clinical trials could validate therapeutic claims
- Integrating with existing traditional medicine frameworks to expand acceptance
- Expanding into markets where herbal and natural remedies are preferred
- Positioning as an immune-boosting adjunct in viral infections during pandemics
Key Takeaways
- CORTROPHIN-ZINC has no registered or ongoing formal clinical trials; its use primarily remains anecdotal or traditional.
- Market penetration is strong in India but minimal globally due to limited clinical validation.
- Future growth hinges on clinical research demonstrating safety and efficacy.
- Regulatory approval outside India remains unlikely without robust data.
- The long-term market potential is uncertain and contingent upon new scientific evidence.
FAQs
1. Is there clinical evidence supporting CORTROPHIN-ZINC’s efficacy?
No substantial randomized trials are publicly available. Its clinical use is based on traditional practices and observational reports.
2. What regulatory approvals does CORTROPHIN-ZINC have?
Approved for use as a supplement or herbal remedy in India; not approved by the FDA or EMA.
3. Could renewed clinical trials boost its market?
Yes. Demonstrated safety and efficacy in high-quality studies could lead to wider acceptance, regulatory approvals, and expanded markets.
4. What are the risks of using CORTROPHIN-ZINC without clinical validation?
Potential risks include unknown side effects, interactions with other drugs, and lack of confirmed benefit, which could undermine patient safety and treatment outcomes.
5. Are competing zinc supplements better validated?
Most zinc supplements from reputable pharmaceutical companies have undergone product validation, though not necessarily for respiratory illnesses. Their efficacy is better documented compared to CORTROPHIN-ZINC.
Sources:
[1] ClinicalTrials.gov, "CORTROPHIN-ZINC", accessed 2023.
[2] FICCI and Pharmexcil reports on herbal medicine markets, 2022.
[3] Central Drugs Standard Control Organization, Indian drug approvals.
